What a year it has been for Life Science. Dramatic production changes required to provide PPE and ventilators. Vaccines in record time. “Elective” procedures and trials put on hold. The realization that supply and delivery of healthcare need to be reexamined. Still with all this Life Science must move forward. As Life Science becomes more personal, targeted and expensive how do we ensure access and the industries incentive for new and better cures and treatments continues. Join us on May 11 as we discuss all these topics and more!
Dr. Patrick Dixon
Futurist and Physician
Dr. Dixon is an advisor to many of the world’s largest pharma companies who has written 17 books, and has been ranked one of the 20 most influential business thinkers in the world.